Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa with Radiotherapy in Metastatic NSCLC
NCT04560244Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04560244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560244.